Deltex Medical Group (DEMG)

Sector:

Health Care

Index:

FTSE AIM All-Share

 1.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 2.65
  • 52 Week Low: 0.90
  • Currency: UK Pounds
  • Shares Issued: 524.46m
  • Volume: 205,053
  • Market Cap: £7.87m
  • RiskGrade: 456

Deltex points to study as proving its product

By Josh White

Date: Friday 09 Jun 2017

LONDON (ShareCast) - (ShareCast News) - Oesophageal doppler monitoring specialist Deltex Medical Group announced the publication of a new trial showing "excellent results" from using ODM in thoracic surgery on Friday.
The AIM-traded company said the results of the randomised controlled trial of 100 patients undergoing lung surgery at the University of Freiburg in Germany had been published online by the British Journal of Anaesthesia.

Vascular fluids and vasoactive drugs were administered during surgery in accordance with Enhanced Recovery After Surgery Society recommended protocols.

Nine fewer ODM patients - six, compared with 15 - suffered postoperative pulmonary complications, the board said, and ODM patients had a two-day shorter stay in hospital - nine, compared with 11 days.

It was the first published randomised controlled trial studying ODM use during thoracic surgery, Deltex claimed.

"This is excellent news for large numbers of patients undergoing lung resection with one in five of them avoiding a dangerous, life shortening, complication," said chief executive Ewan Phillips.

"The trial allows us to target thoracic surgery on top of those other specific types of surgery where the value of ODM has previously been demonstrated.

"In the NHS in England there are around 40,000 patients a year undergoing higher risk thoracic procedures with a risk of postoperative death within 30 days of 1% or higher and very few of these have fluids or vasoactive drugs administered with the aid of ODM."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

DEMG Market Data

Currency UK Pounds
Share Price 1.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 2.65
52 Week Low 0.90
Volume 205,053
Shares Issued 524.46m
Market Cap £7.87m
RiskGrade 456

DEMG Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
47.47% below the market average47.47% below the market average47.47% below the market average47.47% below the market average47.47% below the market average
45.95% above the sector average45.95% above the sector average45.95% above the sector average45.95% above the sector average45.95% above the sector average
Price Trend
66.67% above the market average66.67% above the market average66.67% above the market average66.67% above the market average66.67% above the market average
20.00% above the sector average20.00% above the sector average20.00% above the sector average20.00% above the sector average20.00% above the sector average
Income Not Available
Growth
56.25% below the market average56.25% below the market average56.25% below the market average56.25% below the market average56.25% below the market average
70.59% below the sector average70.59% below the sector average70.59% below the sector average70.59% below the sector average70.59% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

DEMG Dividends

No dividends found

Trades for 03-Jul-2020

Time Volume / Share Price
16:21 16,316 @ 1.50p
15:22 14,803 @ 1.48p
14:50 1,600 @ 1.48p
11:10 172,334 @ 1.40p

DEMG Key Personnel

Chair Nigel J Keen
CEO Andy Mears

Top of Page